Literature DB >> 25127930

Successful nonsurgical endodontic outcome of a severely affected permanent maxillary canine with dens invaginatus Oehlers type 3.

John K Brooks1, Michael J Ribera2.   

Abstract

INTRODUCTION: The morphogenic complexities of dens invaginatus (DI) Oehlers type 3 in maxillary canines offer significant endodontic challenges.
METHODS: A case report is provided of a 14-year-old female patient who presented with an anomalous-looking permanent maxillary canine associated with a sinus tract. Pulp testing revealed a normal response on the distal aspect of the tooth, whereas the mesial segment tested nonresponsive. A radiolucent lesion was seen on the mesiolateral radicular area adjacent to the severely distended pulp chamber. A gutta-percha point inserted into the sinus tract traced to this same region. The diagnosis was normal pulp coincident with DI Oehlers type 3 with pulp necrosis and chronic apical abscess.
RESULTS: Despite a concerted effort to limit the root canal therapy to only the necrotic canal, its proximity to the normal canal obviated this possibility, entailing endodontic treatment of the entire root canal system. The necrotic pulp space was subjected to sustained irrigation with 5.25% sodium hypochlorite and then completed with 17% ethylenediaminetetraacetic acid. A bolus of gutta-percha was used to create an apical barrier, and then the remainder of the enlarged pulp space was obturated with injectable thermoplasticized gutta-percha. At a 4.5-year recall, there was no clinical and radiographic evidence of infection.
CONCLUSIONS: Endodontic success was accomplished with meticulous efforts of disinfection. Thermoplasticized gutta-percha can offer utility for obturation of anatomically complicated pulp spaces. The use of the dental operating microscope is an invaluable aid for discernment of the intricacies of teeth affected with DI type 3 variant and can enhance clinical outcomes.
Copyright © 2014 American Association of Endodontists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cuspid; dens invaginatus; disinfection; endodontics; root canal obturation

Mesh:

Substances:

Year:  2014        PMID: 25127930     DOI: 10.1016/j.joen.2014.06.008

Source DB:  PubMed          Journal:  J Endod        ISSN: 0099-2399            Impact factor:   4.171


  7 in total

1.  A multidisciplinary management of a type III dens invaginatus in a maxillary permanent canine.

Authors:  P Clarke; N Longridge; L Gartshore
Journal:  Eur Arch Paediatr Dent       Date:  2015-10-01

2.  Dens invaginatus with necrotic pulp in a right maxillary lateral incisor with preserved vitality.

Authors:  Lanza Alessandro; Di Francesco Fabrizio; De Marco Gennaro; Di Stasio Dario; Guidetti Eugenio; Perillo Letizia; Femiano Luigi; Femiano Felice
Journal:  J Conserv Dent       Date:  2018 Jan-Feb

3.  Treatment of type III dens invaginatus in bilateral immature mandibular central incisors: a case report.

Authors:  Jie Zhang; Yuan Wang; Lei Xu; Zhifang Wu; Yan Tu
Journal:  BMC Oral Health       Date:  2022-02-04       Impact factor: 2.757

4.  Successful treatment of dens invaginatus type 3 with infected invagination, vital pulp, and cystic lession: A case report.

Authors:  Ausra Dembinskaite; Rita Veberiene; Vita Machiulskiene
Journal:  Clin Case Rep       Date:  2018-06-25

5.  Non-surgical Removal of Dens Invaginatus in Maxillary Lateral Incisor Using CBCT: Two-year Follow-up Case Report.

Authors:  Babita Pradhan; Yuan Gao; Libang He; Jiyao Li
Journal:  Open Med (Wars)       Date:  2019-10-19

6.  A case report of multiple bilateral dens invaginatus in maxillary anteriors.

Authors:  Shin Hye Chung; You-Jeong Hwang; Sung-Yeop You; Young-Hye Hwang; Soram Oh
Journal:  Restor Dent Endod       Date:  2019-10-21

7.  Prevalence of dens invaginatus in young Israeli population and its association with clinical morphological features of maxillary incisors.

Authors:  Anda Kfir; Nurit Flaisher Salem; Lobna Natour; Zvi Metzger; Noa Sadan; Shlomo Elbahary
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.